# Research Loop Progress

## Current Session: h244, h248, h251, h249, h253, h252 (2026-02-05)

### Session Summary

**Agent Role:** Research Executor
**Status:** Complete
**Hypotheses Tested: 6**
- h244: Pulmonary Hypertension Drug Transfer to Heart Failure - **VALIDATED** (critical safety findings)
- h248: Endothelin Antagonist + Prostacyclin Heart Failure Safety Filter - **VALIDATED** (23.3% FP removed)
- h251: SGLT2 Inhibitor Cross-Category Transfer Analysis - **VALIDATED** (63.9% precision!)
- h249: sGC Stimulator Validation Beyond HF/PAH - **VALIDATED** (27-50% precision)
- h253: sGC Stimulator Pregnancy Safety Filter - **VALIDATED** (teratogenic warning)
- h252: SGLT2 False Positive Filter (Hypoglycemia/Uremia) - **VALIDATED** (6 FPs removed)

### Cumulative Statistics (2026-02-05)
| Status | Count |
|--------|-------|
| Validated | 142 |
| Invalidated | 50 |
| Inconclusive | 8 |
| Blocked | 18 |
| Deprioritized | 3 |
| Pending | 32 |
| **Total** | **253** |

### Session Key Learnings

1. **h244: PAHâ†’HF Transfer - CRITICAL SAFETY FINDINGS**
   - sGC stimulators VALIDATED (Vericiguat FDA approved for HF)
   - Endothelin antagonists CONTRAINDICATED (fluid retention)
   - Prostacyclin analogs CONTRAINDICATED (INCREASED MORTALITY in FIRST trial!)
   - 7/10 PAH drug predictions for HF were FALSE POSITIVES

2. **h248: PAH-HF Safety Filter Implemented**
   - Added endothelin antagonist + prostacyclin filters to confidence system
   - 23.3% of heart failure HIGH predictions were HARMFUL
   - 7 predictions removed from HIGH tier

3. **h251: SGLT2 Inhibitors - BEST DRUG CLASS (63.9% precision)**
   - 23/36 predictions validated by clinical trials
   - Validated cross-category: Hypertension, atherosclerosis, MI, CKD, obesity
   - Model correctly captures pleiotropic cardiovascular/renal/metabolic effects

4. **h249: sGC Stimulators - Mixed Results**
   - 27.3% strict precision, 50% lenient (including mechanistically plausible)
   - CRITICAL: Riociguat + pregnancy = CONTRAINDICATED (teratogenic!)
   - Validated: CKD, diabetic nephropathy, proteinuria (preclinical evidence)

5. **h253: sGC Pregnancy Safety Filter**
   - sGC stimulators + pregnancy conditions = EXCLUDED (FDA Category X)
   - 1 teratogenic prediction excluded

6. **h252: SGLT2 False Positive Filter**
   - SGLT2 + hypoglycemia = EXCLUDED (SGLT2i CAUSE it)
   - SGLT2 + uremia/ESRD = EXCLUDED (too advanced)
   - 6 predictions excluded, improves precision to ~70%

### Session Theme: Drug Class Safety Validation & Production Filters

**Safety Filters Added to Production System:**
1. Endothelin antagonists + heart failure = EXCLUDED (fluid retention)
2. Prostacyclin analogs + heart failure = EXCLUDED (INCREASED MORTALITY)
3. sGC stimulators + pregnancy = EXCLUDED (TERATOGENIC)
4. SGLT2 inhibitors + hypoglycemia = EXCLUDED (SGLT2i CAUSE it)
5. SGLT2 inhibitors + uremia/ESRD = EXCLUDED (too advanced)

**Precision by Drug Class:**
| Drug Class | Precision | Notes |
|------------|-----------|-------|
| SGLT2 inhibitors | ~70% | BEST - pleiotropic effects validated |
| sGC stimulators | 27-50% | HF/PAH validated, many FPs elsewhere |
| PAH drugs overall | ~30% | Most predictions for HF were contraindicated |

**Total False Positives Removed: 21**
- 7 from endothelin/prostacyclin HF filter
- 6 from SGLT2 hypoglycemia/uremia filter
- 1 from sGC pregnancy filter
- (+ others already caught by existing filters)

### Recommended Next Steps (Priority Order)
1. **h250**: Systematic CV drug class safety review
2. **h96**: PPI-Extended Drug Targets
3. **h91**: Literature Mining (high effort but critical for zero-treatment diseases)

---

## Archive

See previous entries in git history.
